<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6737">
  <stage>Registered</stage>
  <submitdate>10/08/2017</submitdate>
  <approvaldate>10/08/2017</approvaldate>
  <nctid>NCT03248882</nctid>
  <trial_identification>
    <studytitle>Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)</studytitle>
    <scientifictitle>A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2017-001156-55</secondaryid>
    <secondaryid>C1171002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nonalcoholic Fatty Liver Disease</healthcondition>
    <healthcondition>Nonalcoholic Steatohepatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - PF-05221304

Placebo Comparator: Placebo - Double-Blind, PF-05221304-matching Placebo

Active Comparator: PF-05221304 - 2 mg - PF-05221304 - 2 mg, once-daily

Active Comparator: PF-05221304 - 10 mg - PF-05221304 - 10 mg, once-daily

Active Comparator: PF-05221304 - 25 mg - PF-05221304 - 25 mg, once-daily

Active Comparator: PF-05221304 - 50 mg - PF-05221304 - 50 mg, once-daily


Treatment: drugs: Placebo
Placebo

Treatment: drugs: PF-05221304
PF-05221304, Experimental Drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluate Dose-Response for Effect on Liver Fat using MRI-PDFF - Percent change from baseline in liver fat, as assessed using MRI-PDFF, at Week 16</outcome>
      <timepoint>16-weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate Dose-Response for Effect on ALT - Percent change from baseline in ALT, at Week 16</outcome>
      <timepoint>16-weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of treatment-emergent adverse events - Spontaneously reported treatment-emergent adverse events</outcome>
      <timepoint>Day 1 to Week 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of clinical laboratory tests - Evaluation of safety-related clinical laboratory tests</outcome>
      <timepoint>Day 1 to Week 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of Vital Signs - Including measurement of Blood Pressure and Pulse rate</outcome>
      <timepoint>Day 1 to Week 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of 12-lead electrocardiograms - Evaluation of cardiac conduction intervals</outcome>
      <timepoint>Day 1 to Week 20</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Body Mass Index &gt;= 25 kg/m2

          -  Body Weight &gt; 50 kg

          -  Liver fat (assessed via MRI-PDFF) &gt;= 8%

          -  Biopsy-proven NASH - diagnosed in previous 24-months

          -  Presumed NASH - per Sponsor's definition

          -  NAFLD with minimal inflammation/fibrosis

          -  Features of Metabolic Syndrome</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Alcohol-induced steatohepatitis or other forms of chronic liver disease

          -  Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus

          -  Severe Renal Impairment

          -  Contraindications for MRI</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>23/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>29/11/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Australian Clinical Research Network - Maroubra</hospital>
    <hospital>Spectrum Medical Imaging - Randwick</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>2035 - Maroubra</postcode>
    <postcode>2013 - Randwick</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03248882</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>